Bulletin
Investor Alert

Market Pulse Archives

Dec. 10, 2019, 8:41 a.m. EST

Correvio stock halted ahead of FDA adcomm

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

SPX

Shares of Correvio Pharma Corp. were halted in advance of a Food and Drug Administration advisory committee meeting for its experimental atrial fibrillation therapy. The drug, Brinavess, is already approved in Europe. The FDA is not required to follow the committee's recommendation but it often does. The FDA is expected to make its decision by Dec. 24. Correvio stock is down 43% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.08% has gained 25%.

/zigman2/quotes/210599714/realtime
US : S&P US
3,145.32
-34.40 -1.08%
Volume: 2.29B
July 7, 2020 5:18p
loading...

Get news alerts on S&P 500 Index — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.